IL319682A - Rna compositions targeting claudin-18.2 - Google Patents
Rna compositions targeting claudin-18.2Info
- Publication number
- IL319682A IL319682A IL319682A IL31968225A IL319682A IL 319682 A IL319682 A IL 319682A IL 319682 A IL319682 A IL 319682A IL 31968225 A IL31968225 A IL 31968225A IL 319682 A IL319682 A IL 319682A
- Authority
- IL
- Israel
- Prior art keywords
- rna compositions
- compositions targeting
- targeting claudin
- claudin
- rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2022/077839 WO2024074211A1 (en) | 2022-10-06 | 2022-10-06 | Rna compositions targeting claudin-18.2 |
| EP2023051126 | 2023-01-18 | ||
| PCT/EP2023/077618 WO2024074634A1 (en) | 2022-10-06 | 2023-10-05 | Rna compositions targeting claudin-18.2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319682A true IL319682A (en) | 2025-05-01 |
Family
ID=88290638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319682A IL319682A (en) | 2022-10-06 | 2023-10-05 | Rna compositions targeting claudin-18.2 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4598954A1 (en) |
| JP (1) | JP2025534447A (en) |
| CN (1) | CN120129702A (en) |
| AU (1) | AU2023357320A1 (en) |
| IL (1) | IL319682A (en) |
| WO (1) | WO2024074634A1 (en) |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965542A (en) | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
| US6410328B1 (en) | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| EP1053023B2 (en) | 1998-02-03 | 2011-03-30 | Protiva Biotherapeutics Inc. | Systemic delivery of serum stable plasmid lipid particles for cancer therapy |
| US6211140B1 (en) | 1999-07-26 | 2001-04-03 | The Procter & Gamble Company | Cationic charge boosting systems |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP2338478B1 (en) | 2002-06-28 | 2014-07-23 | Protiva Biotherapeutics Inc. | Method for producing liposomes |
| JP4951338B2 (en) | 2003-07-16 | 2012-06-13 | プロチバ バイオセラピューティクス インコーポレイティッド | Interfering RNA encapsulated in lipid |
| US6927663B2 (en) | 2003-07-23 | 2005-08-09 | Cardiac Pacemakers, Inc. | Flyback transformer wire attach method to printed circuit board |
| JP4842821B2 (en) | 2003-09-15 | 2011-12-21 | プロチバ バイオセラピューティクス インコーポレイティッド | Polyethylene glycol modified lipid compounds and uses thereof |
| AU2005252273B2 (en) | 2004-06-07 | 2011-04-28 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| EP1937213B1 (en) | 2005-07-27 | 2017-10-25 | Protiva Biotherapeutics Inc. | Systems and methods for manufacturing liposomes |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| JP5475753B2 (en) | 2008-04-15 | 2014-04-16 | プロチバ バイオセラピューティクス インコーポレイティッド | Lipid formulations for nucleic acid delivery |
| MX338780B (en) | 2008-11-10 | 2016-05-02 | Alnylam Pharmaceuticals Inc | Novel lipids and compositions for the delivery of therapeutics. |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| WO2011066651A1 (en) | 2009-12-01 | 2011-06-09 | Protiva Biotherapeutics, Inc. | Snalp formulations containing antioxidants |
| EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| EP3494963A1 (en) | 2009-12-18 | 2019-06-12 | The University of British Columbia | Methods and compositions for delivery of nucleic acids |
| EP2569276B1 (en) | 2010-05-12 | 2021-02-24 | Arbutus Biopharma Corporation | Novel cationic lipids and methods of use thereof |
| EP4481047A3 (en) | 2010-06-03 | 2025-04-16 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| AU2012207606B2 (en) | 2011-01-11 | 2017-02-23 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| WO2013049328A1 (en) | 2011-09-27 | 2013-04-04 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
| US8762704B2 (en) | 2011-09-29 | 2014-06-24 | Apple Inc. | Customized content for electronic devices |
| EP2788006A1 (en) | 2011-12-07 | 2014-10-15 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| CA2856737C (en) | 2011-12-07 | 2023-09-26 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
| WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| AU2012352180A1 (en) | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| US9415109B2 (en) | 2012-07-06 | 2016-08-16 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
| KR101890951B1 (en) | 2012-12-20 | 2018-08-22 | 에스케이이노베이션 주식회사 | Integrated Drying Gasification Process for Co-producing Synthesis Gas and High Quality of Coals |
| CN106795096B (en) | 2014-06-25 | 2020-05-29 | 爱康泰生治疗公司 | Novel lipid and lipid nanoparticle formulations for nucleic acid delivery |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| HRP20240865T1 (en) | 2015-06-29 | 2024-10-11 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| SI3954225T1 (en) | 2015-09-21 | 2024-03-29 | Trilink Biotechnologies, Llc | Initiating capped oligonucleotide primers for synthesizing 5'-capped rnas |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| AU2016343803B2 (en) | 2015-10-28 | 2021-04-29 | Acuitas Therapeutics, Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| SMT202100681T1 (en) | 2016-04-22 | 2022-01-10 | BioNTech SE | Methods for providing single-stranded rna |
| EP3532103B1 (en) | 2016-10-26 | 2025-12-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| BR112019017743A2 (en) * | 2017-02-28 | 2020-04-07 | Sanofi Sa | therapeutic rna |
| WO2020041655A1 (en) * | 2018-08-24 | 2020-02-27 | Sanofi | Therapeutic rna for solid tumor cancers |
| WO2021198157A1 (en) * | 2020-03-30 | 2021-10-07 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| KR20230002571A (en) * | 2020-04-14 | 2023-01-05 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | Large sequence pan-coronavirus vaccine composition |
| WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
-
2023
- 2023-10-05 AU AU2023357320A patent/AU2023357320A1/en active Pending
- 2023-10-05 CN CN202380076510.4A patent/CN120129702A/en active Pending
- 2023-10-05 JP JP2025519708A patent/JP2025534447A/en active Pending
- 2023-10-05 WO PCT/EP2023/077618 patent/WO2024074634A1/en not_active Ceased
- 2023-10-05 IL IL319682A patent/IL319682A/en unknown
- 2023-10-05 EP EP23785777.6A patent/EP4598954A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN120129702A (en) | 2025-06-10 |
| EP4598954A1 (en) | 2025-08-13 |
| AU2023357320A1 (en) | 2025-04-17 |
| JP2025534447A (en) | 2025-10-15 |
| WO2024074634A1 (en) | 2024-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4045637A4 (en) | Engineered muscle targeting compositions | |
| IL299431A (en) | Engineered muscle targeting compositions | |
| WO2018191278A3 (en) | Targeted compositions | |
| IL292766A (en) | Antibody-drug conjugates targeting claudin 18.2 | |
| EP1991248A4 (en) | Antidepressant prodrugs | |
| IL321083A (en) | Advanced rna targeting (arnatar) | |
| IL319682A (en) | Rna compositions targeting claudin-18.2 | |
| CA3269729A1 (en) | Rna compositions targeting claudin-18.2 | |
| WO2008107771A3 (en) | 2',3'-di-o-acyl-5-fluoronucleosides | |
| IL316630A (en) | Rna compositions targeting hiv | |
| HK40092141A (en) | Antibody-drug conjugates targeting claudin 18.2 | |
| HK40123347A (en) | Rna compositions targeting hiv | |
| HK40087002A (en) | Engineered muscle targeting compositions | |
| HK40072861A (en) | Engineered muscle targeting compositions | |
| GB202216848D0 (en) | Jackbag 2.0 | |
| GB202213970D0 (en) | 5000%vv3davtripple4000x10,000xshohryakuvaixonevaivai137millioncirclexdotshohryakuvaizonevai Shohryakuvaizonevaivai13millioncirclexdotgagaligagaligalifaligalig | |
| GB202213971D0 (en) | 5000%vv3davtripple4000x10,000xshohryakuvai137millioncirclexdotshohryakuvaizonevai shohryakuvaizonevaivai13millioncircleexdotgagaligagaligaligaligaligalishohry | |
| GB202213972D0 (en) | 5000%vv3davtripple4000x10,000xshohryakuvaizonevaivai137millioncirclexdot shohryakuvaivai13millioncirclexdotgagaligagaligaligaligaligaalishohryakuvaishohryakuv | |
| HK40117299A (en) | Antibody-drug conjugate targeting claudin18.2 | |
| Pourgholam-Amiji et al. | JSSA-Volume 13-Issue 4-Pages 1-92 | |
| CA3275761A1 (en) | Advanced rna targeting (arnatar) | |
| HK40118739A (en) | Advanced rna targeting (arnatar) | |
| CA3270378A1 (en) | Compositions and methods for targeting, editing, or modifying genes | |
| HK40111667A (en) | Antisense oligonucleotides targeting unc13a | |
| HK40106800A (en) | Antisense oligonucleotides targeting actl6b |